Citius Oncology, Inc. (CTOR) Balance Sheet

NASDAQ: CTORAssets, liabilities, debt and equity over 4 years.

CTOR balance sheet, FY2025

September 30, 2025 · U.S. dollars

$100.9M assets = $56.1M liabilities + $44.9M equity

Both columns are drawn to the same scale: what CTOR owns equals what it owes plus shareholders’ equity. Hover a block for its value.

CTOR financial health

Current ratio0.56

Tight · current assets cover current liabilities 0.56×

Debt / equity0.08

Low leverage · $0.08 of debt for each $1 of equity

Equity / assets44.4%

Equity-funded · of assets funded by shareholders

Cash / debt103.3%

Cash covers debt · cash & short-term investments vs total debt

Goodwill & intangibles72.7%

Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal FY2025.

CTOR balance sheet trends, FY2022–FY2025

Citius Oncology, Inc. balance sheet trends
Metric	Then	Latest	Change
Total assets	$42.7MFY2022	$100.9MFY2025	+33.2%/yr
Total liabilities	$6.4MFY2022	$56.1MFY2025	+105.9%/yr
Shareholders’ equity	$36.3MFY2022	$44.9MFY2025	+7.3%/yr
Cash & short-term investments	$289,175FY2022	$3.9MFY2025	+138.5%/yr
Total debt	$3.8MFY2024	$3.8MFY2025	0.0%/yr
Net cash (debt)	−$3.8MFY2024	$124,797FY2025	+$3.9M
Working capital	−$3.2MFY2022	−$21.9MFY2025	−$18.8M
Book value per share	$0.40FY2022	$0.61FY2025	+15.0%/yr
Current ratio	0.46FY2022	0.56FY2025	+0.10
Debt / equity	0.08FY2024	0.08FY2025	0.00
Shares outstanding	90.2MFY2022	73.3MFY2025	−6.7%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

CTOR assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

CTOR liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

CTOR debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

CTOR balance sheet

Citius Oncology, Inc. annual balance sheet
	FY2025	FY2024	FY2023	FY2022
Assets
Cash & short-term investments	$3.9M	$112	$26,523	$289,175
Cash & equivalents	$3.9M	$112	$26,523	$289,175
Receivables	$0	$0	$0	$0
Inventory	$22.3M	$8.3M	$0	$0
Other current assets	$1.3M	$2.7M	$7.7M	$2.4M
Total current assets	$27.5M	$11.0M	$7.7M	$2.7M
Property, plant & equipment (net)	$0	$0	$0	$0
Goodwill & intangible assets	$73.4M	$73.4M	$40.0M	$40.0M
Long-term investments	$0	$0	$0	$0
Other non-current assets	$0	$0	$0	$0
Total assets	$100.9M	$84.4M	$47.7M	$42.7M
Liabilities
Accounts payable	$13.2M	$3.7M	$1.3M	$92,311
Total current liabilities	$49.5M	$32.7M	$21.0M	$5.8M
Long-term debt	$3.8M	$3.8M	$0	$0
Other long-term liabilities	$2.8M	$1.7M	$1.2M	$576,000
Total liabilities	$56.1M	$38.2M	$22.2M	$6.4M
Shareholders' equity
Common stock & paid-in capital	$8,351	$7,155	$6,750	$6,750
Retained earnings (deficit)	−$64.0M	−$39.3M	−$18.1M	−$5.4M
Total shareholders' equity	$44.9M	$46.1M	$25.5M	$36.3M
Key figures
Total debt	$3.8M	$3.8M	—	—
Net cash (debt)	$124,797	−$3.8M	—	—
Working capital	−$21.9M	−$21.7M	−$13.3M	−$3.2M
Tangible book value	−$28.5M	−$27.3M	−$14.5M	−$3.7M
Book value per share	$0.61	$0.64	$0.29	$0.40
Shares outstanding	73.3M	71.6M	89.5M	90.2M
Current ratio	0.56	0.34	0.37	0.46
Quick ratio	0.08	0.00	0.00	0.05
Debt / equity	0.08	0.08	—	—
Equity / assets	44.4%	54.7%	53.5%	85.0%

Citius Oncology, Inc. quarterly balance sheet
	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23
Assets
Cash & short-term investments	$16.6M	$2.6M	$7.3M	$3.9M	$112	$112	$112	$112	$261	$33,330	$32,745	$26,523
Cash & equivalents	$16.6M	$2.6M	$7.3M	$3.9M	$112	$112	$112	$112	$261	$33,330	$32,745	$26,523
Receivables	$686,235	$1.1M	$4.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$22.6M	$22.7M	$22.6M	$22.3M	$17.2M	$15.3M	$14.4M	$8.3M	$0	$0	$0	$0
Other current assets	$2.8M	$3.1M	$3.2M	$1.3M	$1.1M	$2.7M	$2.7M	$2.7M	$10.0M	$8.9M	$7.7M	$7.7M
Total current assets	$42.7M	$29.4M	$37.1M	$27.5M	$18.3M	$18.0M	$17.1M	$11.0M	$10.0M	$8.9M	$7.7M	$7.7M
Property, plant & equipment (net)	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill & intangible assets	$69.4M	$71.1M	$72.8M	$73.4M	$73.4M	$73.4M	$73.4M	$73.4M	$0	$0	$0	$40.0M
Long-term investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Other non-current assets	$0	$169,252	$0	$0	$0	$0	$0	$0	$40.0M	$40.0M	$40.0M	$0
Total assets	$112.1M	$100.7M	$110.0M	$100.9M	$91.7M	$91.4M	$90.5M	$84.4M	$50.0M	$48.9M	$47.7M	$47.7M
Liabilities
Accounts payable	$7.3M	$8.9M	$10.4M	$13.2M	$8.7M	$7.7M	$5.9M	$3.7M	—	$503,913	$205,018	$1.3M
Short-term debt	—	—	—	—	—	—	—	—	$1.7M	$1.5M	—	—
Total current liabilities	$58.8M	$58.8M	$44.7M	$49.5M	$53.0M	$49.7M	$43.4M	$32.7M	$31.4M	$27.6M	$23.7M	$21.0M
Long-term debt	$10.2M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$0	$0	$0	$0
Other long-term liabilities	$2.7M	$2.8M	$3.0M	$2.8M	$2.5M	$2.3M	$2.0M	$1.7M	$1.6M	$1.4M	$1.3M	$1.2M
Total liabilities	$71.7M	$65.4M	$51.6M	$56.1M	$59.3M	$55.8M	$49.2M	$38.2M	$33.0M	$29.1M	$25.0M	$22.2M
Shareholders' equity
Common stock & paid-in capital	$10,576	$9,298	$8,480	$8,351	$7,155	$7,155	$7,155	$7,155	$6,750	$6,750	$6,750	$6,750
Retained earnings (deficit)	−$105.1M	−$96.2M	−$69.6M	−$64.0M	−$59.0M	−$53.7M	−$45.9M	−$39.3M	−$32.5M	−$27.7M	−$22.9M	−$18.1M
Total shareholders' equity	$40.4M	$35.3M	$58.4M	$44.9M	$32.4M	$35.6M	$41.3M	$46.1M	$17.0M	$19.8M	$22.7M	$25.5M
Key figures
Total debt	$10.2M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$3.8M	$1.7M	$1.5M	—	—
Net cash (debt)	$6.4M	−$1.2M	$3.5M	$124,797	−$3.8M	−$3.8M	−$3.8M	−$3.8M	−$1.7M	−$1.5M	—	—
Working capital	−$16.1M	−$29.4M	−$7.6M	−$21.9M	−$34.7M	−$31.7M	−$26.3M	−$21.7M	−$21.4M	−$18.7M	−$16.0M	−$13.3M
Tangible book value	−$29.0M	−$35.8M	−$14.4M	−$28.5M	−$41.0M	−$37.8M	−$32.1M	−$27.3M	$17.0M	$19.8M	$22.7M	−$14.5M
Book value per share	$0.37	$0.35	$0.67	$0.55	$0.45	$0.50	$0.58	$0.64	$0.26	$0.30	$0.25	$0.29
Shares outstanding	107.9M	100.0M	87.5M	80.9M	71.6M	71.6M	71.6M	71.6M	66.5M	66.5M	89.4M	89.5M
Current ratio	0.73	0.50	0.83	0.56	0.35	0.36	0.39	0.34	0.32	0.32	0.33	0.37
Quick ratio	0.29	0.06	0.25	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt / equity	0.25	0.11	0.07	0.08	0.12	0.11	0.09	0.08	0.10	0.08	—	—
Equity / assets	36.0%	35.0%	53.1%	44.4%	35.3%	39.0%	45.6%	54.7%	34.1%	40.6%	47.6%	53.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 30, 2025); data from EODHD.

CTOR financial position

At the end of fiscal 2025 (September 30, 2025), Citius Oncology had total assets of $100.9 million (up 19.6% from a year earlier), total liabilities of $56.1 million and shareholders' equity of $44.9 million. It held $3.9 million in cash and short-term investments against $3.8 million of debt, a net cash position of $0.1 million. Its current ratio was 0.56. In the latest quarter (ended June 30, 2026) total assets were $112.1 million and equity $40.4 million.

Related: CTOR income statement, CTOR cash flow statement, CTOR key metrics. See the CTOR stock overview for the latest quote and news.

CTOR balance sheet FAQ

What are Citius Oncology's total assets?

Citius Oncology reported total assets of $100.9 million at the end of fiscal 2025 (September 30, 2025), compared with $84.4 million a year earlier.

How much debt does Citius Oncology have?

Citius Oncology had $3.8 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.08.

How much cash does Citius Oncology have?

Citius Oncology held $3.9 million in cash and short-term investments at the end of fiscal 2025; with $3.8 million of debt that is net cash of $0.1 million.

What is Citius Oncology's book value?

Citius Oncology's shareholders' equity (book value) was $44.9 million at the end of fiscal 2025, or $0.61 per share.

What is Citius Oncology's current ratio?

Citius Oncology had current assets of $27.5 million and current liabilities of $49.5 million, a current ratio of 0.56 (current liabilities exceed current assets).

How much goodwill does Citius Oncology have?

Citius Oncology carried $73.4 million of goodwill and intangible assets, 72.7% of total assets, at the end of fiscal 2025.